Lifecore Biomedical (LFCR) Competitors

LENZ Therapeutics (NASDAQ:LENZ) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Which has stronger earnings & valuation, LENZ or LFCR?

Lifecore Biomedical has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	N/A	N/A	-$49.77M	-$1.90	-20.80
Lifecore Biomedical	$128.87M	2.22	-$38.72M	-$1.31	-5.84

Is LENZ or LFCR more profitable?

LENZ Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -31.70%. LENZ Therapeutics' return on equity of -25.63% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-25.63%	-24.43%
Lifecore Biomedical	-31.70%	-846.51%	-13.03%

Do institutionals & insiders have more ownership in LENZ or LFCR?

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by insiders. Comparatively, 32.2% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media prefer LENZ or LFCR?

In the previous week, LENZ Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for LENZ Therapeutics and 3 mentions for Lifecore Biomedical. LENZ Therapeutics' average media sentiment score of 0.76 beat Lifecore Biomedical's score of 0.60 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, LENZ or LFCR?

LENZ Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Do analysts recommend LENZ or LFCR?

LENZ Therapeutics currently has a consensus price target of $49.60, suggesting a potential upside of 25.52%. Lifecore Biomedical has a consensus price target of $8.00, suggesting a potential upside of 4.51%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

LENZ Therapeutics and Lifecore Biomedical tied by winning 8 of the 16 factors compared between the two stocks.